Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist

(2015) Olivier Dewit et al.   GASTROENTEROLOGY

90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial

(2015) Geert R. D'Haens et al.   GASTROENTEROLOGY

Review article: anti-adhesion therapies for inflammatory bowel disease

(2014) T. Lobatón et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014

(2014) Anil Asthana et al.   CURRENT DRUG TARGETS

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis

(2014) Michel Varrin-Doyer et al.   EXPERIMENTAL NEUROLOGY

863 Tralokinumab (CAT-354), an Interleukin 13 Antibody, in Moderate to Severe Ulcerative Colitis: A Phase 2A Randomized Placebo-Controlled Study

(2014) Silvio Danese et al.   GASTROENTEROLOGY

P516 Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: Results from an anti-IL-13 antibody study

(2014) W. Reinisch et al.   Journal of Crohns & Colitis

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket

(2014) Diane D'allard et al.   PLoS One

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

(2013) M. Rinaudo-Gaujous et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Disease-Modifying Anti-Inflammatory Bowel Disease Drugs (DMAIDs): The Missing Term in the Literature

(2013) Laurent Peyrin-Biroulet   AMERICAN JOURNAL OF GASTROENTEROLOGY

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib: Janus Bifrons in Ulcerative Colitis Treatment

(2013) Laurent Peyrin–Biroulet et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial

(2013) B. Sands et al.   Journal of Crohns & Colitis

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease

(2013) Mehmet Coskun et al.   PHARMACOLOGICAL RESEARCH

Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy

(2013) Klaudia Farkas et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

(2012) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Biosimilars: what clinicians should know

(2012) M. Weise et al.   BLOOD

Role of mast cells in mucosal diseases: current concepts and strategies for treatment

(2012) Lianne Beunk et al.   Expert Review of Clinical Immunology

Interleukin 13 and its role in gut defence and inflammation

(2012) Peter Mannon et al.   GUT

Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease

(2012) Giovanni Monteleone et al.   MOLECULAR THERAPY

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Conventional Medical Management of Inflammatory Bowel Disease

(2011) Daniel Burger et al.   GASTROENTEROLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

New therapies for inflammatory bowel disease: from the bench to the bedside

(2011) Silvio Danese   GUT

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

(2011) Laurent Peyrin-Biroulet et al.   GUT

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

(2011) Kearkiat Praditpornsilpa et al.   KIDNEY INTERNATIONAL

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

(2010) Richard J. Riese et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

(2010) W. J. Sandborn et al.   GUT

The Natural History of Adult Crohn's Disease in Population-Based Cohorts

(2009) Laurent Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Controlling the cost of innovative cancer therapeutics

(2009) Nafees N. Malik   Nature Reviews Clinical Oncology

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

(2009) Jacques Tebib et al.   ARTHRITIS RESEARCH & THERAPY

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

(2008) Jonathan Kay et al.   ARTHRITIS AND RHEUMATISM

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

(2008) Brian G. Feagan et al.   GASTROENTEROLOGY

Crohn's disease: beyond antagonists of tumour necrosis factor

(2008) Laurent Peyrin-Biroulet et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET